BINEX Co., Ltd.

KOSDAQ:A053030 Stock Report

Market Cap: ₩546.5b

BINEX Past Earnings Performance

Past criteria checks 0/6

BINEX's earnings have been declining at an average annual rate of -52.3%, while the Pharmaceuticals industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 2% per year.

Key information

-52.34%

Earnings growth rate

-52.27%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate1.96%
Return on equity-13.73%
Net Margin-18.05%
Last Earnings Update31 Mar 2025

Recent past performance updates

We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings

Mar 22
We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings

Recent updates

Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?

May 15
Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?

What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price Crash

Mar 05
What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price Crash

Here's Why BINEX (KOSDAQ:053030) Can Afford Some Debt

Feb 13
Here's Why BINEX (KOSDAQ:053030) Can Afford Some Debt

Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%

Jan 08
Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%

BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Nov 18
BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?

Oct 23
Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?

Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%

Sep 01
Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%

Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%

Jul 01
Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%

BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk

Apr 17
BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk

We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings

Mar 22
We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings

BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up

Feb 26
BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up

Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?

Mar 18
Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?

If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today

Jan 28
If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today

Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Dec 24
Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Revenue & Expenses Breakdown

How BINEX makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A053030 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25140,128-25,28748,1661,261
31 Dec 24130,051-35,07149,9111,201
30 Sep 24129,614-25,17250,0551,184
30 Jun 24128,302-18,86050,8951,328
31 Mar 24136,335-12,16551,9561,255
31 Dec 23154,8254,67153,8051,310
30 Sep 23160,7852,84556,3462,246
30 Jun 23168,71513,45155,8211,928
31 Mar 23169,56617,62553,9731,821
31 Dec 22156,67712,44550,8661,618
30 Sep 22154,96916,51148,513-153
30 Jun 22148,84716,35446,7935
31 Mar 22137,08112,56546,070181
31 Dec 21134,39919,09445,916384
30 Sep 21129,47410,14445,0871,174
30 Jun 21129,0319,39045,6221,157
31 Mar 21134,42413,27844,2771,112
31 Dec 20132,9766,41244,4861,097
30 Sep 20131,55013,97043,3871,104
30 Jun 20129,09711,46342,9531,121
31 Mar 20127,0648,73543,9561,092
31 Dec 19125,2598,50443,1791,035
30 Sep 19122,94213,09240,6351,009
30 Jun 19119,09913,56540,4081,000
31 Mar 19111,2038,87840,394945
31 Dec 18104,0436,33739,297895
30 Sep 1891,167-4,23240,651785
30 Jun 1884,136-9,32539,074658
31 Mar 1879,031-12,41935,551660
31 Dec 1778,026-10,79734,419622
30 Jun 1780,782-7,52830,512704
31 Mar 1781,500-3,06529,823761
31 Dec 1680,924-3,14429,053818
30 Sep 1677,576-12,16929,469885
30 Jun 1674,890-10,19627,535956
31 Mar 1671,804-9,55326,4171,043
31 Dec 1566,539-9,28924,3241,169
30 Sep 1456,724-2,35721,2311,404
30 Jun 1458,746-3,15821,3281,682

Quality Earnings: A053030 is currently unprofitable.

Growing Profit Margin: A053030 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A053030 is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.

Accelerating Growth: Unable to compare A053030's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A053030 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.6%).

Return on Equity

High ROE: A053030 has a negative Return on Equity (-13.73%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 14:30
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BINEX Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Heeyoung LeeDaishin Securities Co. Ltd.
Sang-Hun LeeiM Securities
Sung Hwan ChoiKyobo Securities Co., Ltd